About Us
-
We align with evolving global regulatory trends, including FDA initiatives, to support a shift toward reduced reliance on animal models.
-
We integrate micro-/nano-fabrication technologies with stem cell biology to engineer advanced, human-relevant tissue and organoid systems.
-
Our iPSC-derived organoid platforms enable disease modeling and drug evaluation.
Technology
-
Self-Sustained Traveling-Wave–Based Cardiac Maturation
We employ a self-generated traveling wave mechanism that does not require external pacing devices to functionally train immature iPSC-derived cardiomyocytes, promoting electrophysiological and mechanical maturation.
-
Dual Excitation–Contraction Recording System
We develop a dual excitation–contraction recording system that enables simultaneous measurement of electrical activity and contractile force in cardiomyocytes and engineered cardiac tissues, providing comprehensive electromechanical functional assessment.
-
Cell evaluation
We employ a combination of Raman spectroscopy, molecular biology techniques, and other advanced analytical approaches to comprehensively evaluate cellular function, physiological status, and resistance to stress or injury. By integrating AI-powered data analysis, we generate detailed and actionable cell characterization reports, providing deep insights into cell quality, functionality, and therapeutic potential.
Company Profile
Company Name
EngiTissue Design Co., Ltd.
Date of Establishment
2024.12.26
Head Office
Techno Alliance Building C, 2-8 Yamadaoka, Suita, Osaka 565-0871 Japan
Laboratory
Room 319, Photonics Center (P3), 2-1 Yamadaoka, Suita, Osaka 565-0871 Japan
Business Activities
-
Design and manufacturing of iPSC-derived organoids
-
Development of 3D tissue platforms for disease modeling and drug screening
-
Cardiac tissue chips for cardiotoxicity and drug efficacy evaluation
-
Technical development and collaborative research support in tissue engineering
Main Clients
-
Universities and public research institutions
-
Pharmaceutical and biotechnology companies
-
Contract Research Organizations (CROs)
Capital
JPY 100 million